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background: Evaluation of OAC utilization and patient characteristics in non-valvular atrial fibrillation (AF) pre-/post-introduction of novel oral 
anticoagulants (NOAC).
methods: A retrospective cohort study was conducted using the Truven Health MarketScan® Research Databases from Jan 2006 to Jul 2012. 
Patients >=18 years old with newly diagnosed with AF (ICD-9 427.31 or 472.32) and 6 months of continuous enrollment pre- and 6 months post- AF 
diagnosis were included. Patients with valvular heart disease, cardiac surgery, a diagnosis for AF or a prescription for an OAC in the 6 months prior to 
the AF diagnosis were excluded. The post-NOAC period started 10/21/2010 (FDA approval dabigatran). For AF patients with an OAC prescription, the 
index date was defined as the first prescription after the AF diagnosis. For AF patients with no OAC prescription, the index date was the date of the 
AF diagnosis. Based on their index date, AF patients were categorized to pre- or post-NOAC periods, respectively. OAC utilization, demographic and 
clinical characteristics were compared using students’ t test or test of proportions. Multivariate analysis was conducted to assess factors associated 
with OAC treatment.
results: There were 183,450 eligible patients (147,168 pre-NOAC: 36,282 post-NOAC). The proportion of patients treated with OAC was slightly 
increased in the post- vs. pre-NOAC period (33.7% vs. 31.7%; P < .001). Mean (SD) CHA2DS2-VASc score among OAC treated patients were 0.94 
(0.95) and 0.89 (0.93) in the post- vs. pre-NOAC period (P 2 declined from the pre- to post-NOAC period (62.4 to 58.8%; P < .001). Statistically 
significant factors associated with OAC treatment vs. non-OAC treatment were similar in both periods. Factors associated with increased OAC 
utilization were prior pulmonary embolism, ischemic stroke, hypertension, diabetes, heart failure and increasing age, while patients with prior 
bleeding events, dyspepsia and renal disease were less likely to be treated with OACs.
conclusions: Despite the introduction of NOAC, the proportion of AF patients receiving OAC was still low. Increased OAC utilization was associated 
with increasing age, diagnosis of HTN, diabetes or HF and prior stroke or PE.
